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Hypersensitivity pneumonitis (HP) is an inflam-
matory lung disease that results from repeated in-
halation of aerosolized antigens (Selman, 2003). 
The etiologic agents are composed of a wide   
variety of organic particles (e.g., mammalian and 
avian proteins, fungi, and bacteria) and certain 
small-molecular-weight volatile and nonvolatile 
chemical compounds. The severity of the in-
flammatory response depends on the nature of 
the antigen, the quantity and duration of expo-
sure, and host–environment interactions (Selman, 
2003). In chronically exposed patients, pulmo-
nary fibrosis (PF) occurs in up to 41% of cases, 
resulting in irreversible pulmonary dysfunction 
and right heart failure (Mönkäre and Haahtela, 
1987; Bourke et al., 1989; Lalancette et al., 1993; 
Yoshizawa et al., 1999). Importantly, lung fibro-
sis is an independent predictor of mortality in 
these patients, with a 5-yr mortality of 27% and a 
median survival of 13 yr (Vourlekis et al., 2004). 
Although PF is associated with numerous diffuse 
lung diseases, including autoimmune diseases 
(e.g., rheumatoid arthritis and systemic sclerosis), 
idiopathic PF, and sarcoidosis, its pathogenesis is 
poorly understood with few therapeutic options 
that arrest progression of fibrotic disease (Luzina 
et al., 2008).
 T cells are a unique subset of lympho-
cytes  whose  function  is  poorly  understood. 
These cells, however, have been implicated in 
the regulation of the immune response gener-
ated against microbial pathogens and allergens 
(Born et al., 2007). The location of  T cells 
in the subepithelium of alveolar and nonalveo-
lar regions of the lung (Wands et al., 2005) sug-
gests that these cells play an important role in 
the immune response directed against inhaled 
particles such as microbial pathogens (Nanno   
et al., 2007). We recently reported that V6/V1+ 
 T cells isolated from the lung of mice 
chronically exposed to Bacillus subtilis express 
IL-17A (Simonian et al., 2009a). In this model 
of HP, C57BL/6 mice repeatedly treated with 
B. subtilis by nasal inhalation develop mono-
nuclear infiltrates in the lung and PF that mimics 
the human disease (Simonian et al., 2006, 2009a; 
Barrera et al., 2008). Interestingly, large numbers 
of  T cells, nearly all of which are V6/V1+, 
accumulate in the lung in response to B. sub-
tilis and attenuate lung inflammation and fibrosis 
upon continued exposure to this ubiquitous 
environmental microorganism (Simonian et al., 
2006). In the absence of  T cells, TCR-/ 
mice treated with B. subtilis have accelerated 
lung fibrosis but similar levels of IL-17A to 
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Inflammation-induced pulmonary fibrosis (PF) leads to irreversible loss of lung function and 
is a predictor of mortality in numerous lung diseases. Why some subjects with lung inflam-
mation but not others develop PF is unclear. In a mouse model of hypersensitivity pneumoni-
tis that progresses to lung fibrosis upon repeated exposure to the ubiquitous microorganism 
Bacillus subtilis,  T cells expand in the lung and inhibit collagen deposition. We show that 
a subset of these  cells represents the predominant source of the Th17 cytokine IL-22 in 
this model. Preventing expression of IL-22, either by mutating the aryl hydrocarbon receptor 
(AhR) or inhibiting AhR signaling, accelerated lung fibrosis. Direct blockade of IL-22 also 
enhanced collagen deposition in the lung, whereas administration of recombinant IL-22 
inhibited lung fibrosis. Moreover, the presence of protective  T cells and IL-22 diminished 
recruitment of CD4+ T cells to lung. These data reveal a protective pathway that involves the 
inhibition of  T cells by regulatory IL-22–secreting  T cells.
©  2010  Simonian  et  al.  This  article  is  distributed  under  the  terms  of  an   
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six 
months after the publication date (see http://www.rupress.org/terms). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons.
org/licenses/by-nc-sa/3.0/).
T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e2240  T cells in lung inflammation and fibrosis | Simonian et al.
those of WT mice as the result of a compensatory increase   
in IL-17A expression by CD4+ T cells. Conversely, IL-22 
levels are reduced in TCR-/ mice (Simonian et al., 
2009a), suggesting that IL-22 may be an important mecha-
nism by which V6/V1+  T cells attenuate lung inflam-
mation and fibrosis.
In this paper, we show that V6/V1+  T cells are the 
predominant cell type in the lung producing IL-22 in response 
to chronic B. subtilis exposure. In addition, these  T cells 
differentially  express  IL-17A  and  IL-22,  with  IL-22  being   
expressed  by  a  subset  of  IL-17F–producing  V6/V1+  
 T cells. In the presence of the d allele of the aryl hydrocar-
bon receptor (AhR), AhRd/d mice had reduced levels of IL-22 
with accelerated collagen deposition in the lung. Administra-
tion of intratracheal recombinant mouse IL-22 (rIL-22) to   
B. subtilis–exposed AhRd/d and TCR-/ mice significantly re-
duced lung inflammation and CD4+ T cell recruitment to lung 
and collagen deposition, suggesting that V6/V1+  T cells 
regulate lung inflammation and fibrosis through IL-22.
RESULTS
Lung V6/V1+  T cells express IL-22 in response  
to B. subtilis
We recently reported that WT C57BL/6 and homozygous 
V6/V1 transgenic (V6+/+) mice repeatedly exposed to   
B. subtilis have increased IL-22 levels in the lung compared 
with mice deficient in  T cells (TCR-/ mice; Simonian 
et al., 2009a). To determine if  T lymphocytes are an impor-
tant  source  of  IL-22,  we  performed  intracellular  cytokine 
staining on T cells isolated from the lung of WT C57BL/6, 
V6+/+, and TCR-/ mice. Gating on CD3++ T cells,   
6 and 9% of ex vivo V6/V1+  T cells isolated from the   
lung of WT C57BL/6 and V6+/+ mice, respectively, express 
IL-22 after repeated exposure to B. subtilis for four consecutive 
weeks (Fig. 1 A). Consistent with a previous study (Martin   
et al., 2009), IL-22–secreting  T cells also express CCR6 
(not depicted). CD4+ T cells also produced IL-22 (Fig. 1 B), 
but the number of IL-22–expressing V6/V1+  T cells was 
significantly greater than CD4+ T cells in the lung of WT 
C57BL/6 and V6+/+ mice (Fig. 1 C). Although TCR-/ 
mice had increased numbers of IL-22–expressing CD4+ T cells 
in the lung compared with WT C57BL/6 and V6+/+ mice, 
levels of IL-22 were markedly diminished in the absence of   
 T cells (Fig. 1 D). In addition, IL-22 levels were consis-
tently lower in the lung of TCR-/ mice compared with 
V6+/+ mice over the 4-wk time course and significantly re-
duced compared with WT C57BL/6 mice at 3 and 4 wk of re-
peated exposure to B. subtilis (Fig. 1 D). Collectively, these data 
suggest that although  and CD4+ T cells both express IL-22, 
V6/V1+  T lymphocytes are the predominant source of 
IL-22 in the lung in response to repeated B. subtilis exposure.
Differential expression of IL-17A and IL-22 by V6/V1+ 
 T cells
Recent studies show that  T cells isolated from the perito-
neal cavity after injection of heat-killed mycobacteria can   
Figure 1.  IL-22 expression by V6/V1+  and CD4+ T cells.  
(A) Representative density plots of intracellular IL-22 expression in  
V6/V1+  T cells isolated from the lung of homozygous transgenic 
V6/V1 (B6.V6+/+) and WT C57BL/6 mice treated with B. subtilis for  
4 wk. V6/V1+  T cells expressing IL-22 were selected from a bivariate 
dot plot of CD3+/C+ cells from the lymphocyte gate. The percentage of 
IL-22–expressing  T cells is shown. (B) Representative density plots of 
intracellular IL-22 expression in CD4+ T cells isolated from the lung of 
B6.V6+/+, WT C57BL/6, and B6.TCR/ mice treated with B. subtilis for  
4 wk. CD4+ T cells were selected from a bivariate dot plot of CD3+/side 
scatter cells from the lymphocyte gate. The percentage of CD3+CD4+  
T cells expressing IL-22 is shown. (C) Absolute number of IL-22–expressing 
V6/V1+  or CD4+ T cells in the lung of B6.V6+/+, WT C57BL/6, and 
B6.TCR/ mice treated with B. subtilis for 4 wk. Data represent at 
least five individual mice per experiment from at least three separate 
experiments (mean ± SD). (D) IL-22 concentration in the lung of mice 
treated with B. subtilis. Data represent at least five individual mice per 
experiment from at least three separate experiments (mean ± SD). The 
asterisks denote a statistically significant (P < 0.05) difference in con-
centration of IL-22 in the lung of B6.V6+/+ mice compared with B6.
TCR/ mice.JEM VOL. 207, September 27, 2010 
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C57BL/6 and V6+/+ mice (Fig. 3 C). Importantly, microbial 
elimination was similar in all three strains of mice (Simonian 
et al., 2009a).
As shown in Fig. 3 D, V6/V1+  T cells also differ-
entially express IL-17A and IL-17F, with the majority of IL-17F 
expression identified in the less bright population of  T cells 
(Fig. 3 D, Gate C, middle), similar to IL-22. As many as 48 and 
44%  of    T  cells  isolated  from  the  lung  of  B.  subtilis– 
treated V6+/+ mice and WT C57BL/6 mice, respectively, 
expressed IL-17F (Fig. 3 D, Gate A, top). In addition, gating 
express IL-22 (Martin et al., 2009). Similar to CD4+ T cells, 
 T cells expressed either IL-17A alone or both IL-17A and 
IL-22 (Martin et al., 2009). In our model of HP and lung fi-
brosis induced by chronic exposure to B. subtilis, density plots 
of CD3++ T cells revealed two distinct  T cell popula-
tions (Fig. 2 A). Gating on the entire CD3++ T cell popu-
lation (Gate A) demonstrated that  T cells isolated from the 
lung of V6+/+ and WT C57BL/6 mice repeatedly exposed 
to B. subtilis differentially express IL-17A and IL-22 by intra-
cellular cytokine staining (Fig. 2 A, top). In the representative 
examples shown in Fig. 2 A, 5% of CD3++ T cells from the 
lung of WT C57BL/6 mice expressed IL-22, 11% expressed 
IL-17A, and very few cells expressed both cytokines. Con-
versely,  T cells isolated from the spleen of WT C57BL/6 
and V6+/+ mice treated with B. subtilis did not express IL-22 
(Fig. S1), suggesting a compartmentalized immune response 
in the lung directed against B. subtilis.
Gating on the brighter subset of  T cells (Gate B), the 
percentage of IL-17A–expressing  T cells increased with a 
concomitant  decrease  in  the  expression  of  IL-22  in  both 
V6+/+ and WT C57BL/6 mice (Fig. 2 A, middle), suggest-
ing that this population of  T cells more frequently ex-
presses IL-17A. IL-17A expression was as high as 17% in this 
 T cell subset with fewer  T cells expressing IL-22 (2%). 
Gating on the less bright population of  T cells (Gate C) 
resulted  in  an  increased  percentage  of  IL-22–expressing   
 T cells, with as many as 12% of this subset producing IL-22, 
whereas fewer  T cells expressed IL-17A (Fig. 2 A, bot-
tom). Overall, the number of IL-17A–expressing  T cells 
was markedly increased with a concomitant decrease in IL-22 
expression in Gate B, whereas IL-22–expressing  T lym-
phocyte  numbers  were  significantly  increased  in  Gate  C   
(Fig. 2 B). Because the vast majority of  T cells accumulat-
ing in the lung in response to B. subtilis express the V6/V1 
TCR (Fig. 1 A; Simonian et al., 2006), these data demon-
strate that V6/V1+  T cells differentially express IL-17A 
and IL-22 in response to repeated exposure to B. subtilis, sug-
gesting the possibility that subsets of V6/V1+  T cells 
may have distinct functional capabilities.
Differential expression of IL-17A and IL-17F by V6/V1+ 
 T cells
In addition to IL-17A, IL-17F was detected in the lung of 
WT C57BL/6, V6+/+, and TCR-/ mice after repeated 
exposure to B. subtilis for four consecutive weeks (Fig. 3 A). 
As shown in Fig. 3 A, TCR-/ mice have a twofold in-
creased  level  of  IL-17F  in  the  lung  compared  with  WT 
C57BL/6 mice and a 1.6-fold increase compared with V6+/+ 
mice. Gating on CD3+CD4+ T cells, CD4+ T cells from the 
lung of TCR-/ mice treated with B. subtilis differentially 
expressed IL-17A and IL-17F (Fig. 3 B). Unlike IL-17A, 
however, CD4+ T cells expressed high levels of IL-17F even 
in the presence of  T cells in both WT C57BL/6 and 
V6+/+ mice (Fig. 3 B). In addition, the absolute number of 
both IL-17F– and IL-17A–expressing CD4+ T cells was in-
creased in the lung of TCR-/ mice compared with WT 
Figure 2.  Differential expression of IL-22 and IL-17A by V6/V1+ 
 T cells. (A) Representative density plots of intracellular IL-22 and  
IL-17A expression in  T cells isolated from the lung of WT C57BL/6 and 
B6.V6+/+ mice treated with B. subtilis for 4 wk.  T cells expressing  
IL-17A or IL-22 were selected from a bivariate dot plot of CD3+/C+ cells 
from the lymphocyte gate. The percentage of  T cells expressing either 
IL-17A or IL-22 is shown in each quadrant of the density plot. (B) Abso-
lute number of IL-22– or IL-17A–expressing  T cells in the lung of B6.
V6+/+ and WT C57BL/6 treated with B. subtilis for 4 wk using different 
gating strategies labeled A, B, or C. Data represent at least five individual 
mice per experiment from at least three separate experiments (mean ± SD). 
NS, not significant. P > 0.05.2242  T cells in lung inflammation and fibrosis | Simonian et al.
identified in a subset of IL-17F–expressing V6/V1+   
T lymphocytes.
Decreased expression of IL-22 in AhRd/d mice repeatedly 
exposed to B. subtilis
Recent  studies  suggest  that  IL-22  expression  requires  the 
presence of AhR in CD4+ and  T cells (Veldhoen et al., 
2008; Martin et al., 2009). To determine if IL-22 production 
was affected by expression of the d allele on the C57BL/6 
background  in  this  model,  we  treated  AhRd/d  mice  with   
on the less bright population of  T cells confirmed dual 
expression of IL-22 and IL-17F by  T cells isolated from 
the lung of both V6+/+ mice (14%) and WT C57BL/6 
(11%; Fig. 3 D, Gate C, bottom). In addition, numbers of 
IL-17A–expressing  T cells were markedly increased with 
a concomitant decrease in IL-17F expression in Gate B, 
whereas IL-17F–expressing  T lymphocyte numbers were 
increased in Gate C (Fig. 3 E). These findings demonstrate 
that in response to B. subtilis, both  and CD4+ T cells dif-
ferentially express IL-17A and IL-17F, with IL-22 expression 
Figure 3.  Differential expression of IL-17F and IL-17A by V6/V1+  T cells. (A) IL-17F concentration in lung homogenates was analyzed by 
ELISA from WT C57BL/6 (wt), B6.V6+/+ (+/+), and B6.TCR/ (/) mice treated with either B. subtilis or PBS for 4 wk. The mean is shown as a solid line. 
Data are compiled from five individual mice from at least two separate experiments. (B) Representative density plots of intracellular IL-17F and IL-17A 
expression in CD4+ T cells isolated from the lung of WT C57BL/6, B6.V6+/+, and B6.TCR/ mice treated with B. subtilis for 4 wk. CD4+ T cells that ex-
press IL-17F and IL-17A were selected from a bivariate dot plot of CD3+/CD4+-expressing cells in the lymphocyte gate. The percentage of CD4+ T cells 
expressing IL-17A or IL-17F is shown in each quadrant of the density plot. (C) Absolute number of IL-17A– or IL-17F–expressing CD4+ T cells in the lung 
of WT C57BL/6, B6.V6+/+, and B6.TCR/ mice treated with B. subtilis for 4 wk. Data represent at least five individual mice per experiment from at least 
three separate experiments (mean ± SD). (D) Representative density plots of intracellular IL-17F and IL-17A expression in  T cells isolated from the lung 
of WT C57BL/6 and B6.V6+/+ mice treated with B. subtilis for 4 wk.  T cells expressing IL-17A, IL-17F, or IL-22 were selected from a bivariate dot plot of 
CD3+/C+ cells from the lymphocyte gate. The percentage of  T cells expressing IL-17A, IL-17F, or IL-22 is shown in each quadrant of the density plot. 
(E) Absolute number of IL-17F–expressing  T cells in the lung of B6.V6+/+ and WT C57BL/6 treated with B. subtilis for 4 wk using different gating strat-
egies labeled A, B, or C. Data represent at least five individual mice per experiment from at least three separate experiments (mean ± SD).JEM VOL. 207, September 27, 2010 
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that were not significantly different than those of cells from   
B. subtilis–treated WT C57BL/6 mice (Fig. 4, A and B). 
Overall, the number of IL-22–expressing  T cells was de-
creased  in  the  lung  of  AhRd/d  mice  compared  with  WT 
C57BL/6 mice repeatedly exposed to B. subtilis in an identi-
cal  manner,  whereas  numbers  of  IL-17A–  and  IL-17F– 
expressing  T cells were unaffected (Fig. 4 C).
To determine whether decreased expression of IL-22 by 
V6/V1+  T cells affects B. subtilis–induced lung fibrosis, 
AhRd/d  mice  treated  with  B.  subtilis  for  four  consecutive 
weeks were analyzed with Masson trichrome staining. As shown 
in Fig. 5 A, AhRd/d mice developed mononuclear infiltrates 
and collagen deposition in a peribronchovascular distribution 
similar to WT C57BL/6 mice treated in an identical fashion. 
We have previously shown that TCR-/ mice develop 
significantly increased lung fibrosis after   
B.  subtilis  exposure  and  are  included  for 
comparison (Simonian et al., 2009a). By 
quantitative analysis using Sirius red, AhRd/d 
mice develop accelerated lung fibrosis with 
a 1.4-fold increased collagen content in the 
lung compared with B. subtilis–treated WT 
C57BL/6 mice (P < 0.05) and a nearly 
fourfold  increase  in  collagen  deposition 
compared  with  PBS-treated  control  ani-
mals (P < 0.001; Fig. 5 B). In addition, col-
lagen  deposition  in  the  lungs  of  AhRd/d 
mice  at  4  wk  of  repeated  exposure  to   
B. subtilis was similar to the exaggerated   
fibrotic response seen in TCR-/ mice 
B. subtilis. The d allele codes for an AHR protein with re-
duced affinity for known ligands as a result of mutations in its 
ligand-binding site (Okey et al., 1989). As shown in Fig. 4 A, 
AhRd/d mice had decreased levels of IL-22 in the lung com-
pared with WT C57BL/6 mice treated in an identical fashion 
with B. subtilis for 4 wk. Levels of IL-17A and IL-17F, how-
ever,  were  similar  in  the  lung  of  B.  subtilis–treated  WT 
C57BL/6 and AhRd/d mice (Fig. 4 A). As shown in Fig. 4 B, 
 T cells isolated from the lung of B. subtilis–treated AhRd/d 
mice had reduced expression of IL-22 compared with WT 
C57BL/6 mice. In contrast,  T cells maintained the capac-
ity to express IL-17A as compared with WT C57BL/6 mice 
treated in an identical fashion (Fig. 4 B). CD4+ T cells did not 
express significant levels of either IL-22 or IL-17A (Fig. 4 B).   
 and CD4+ T cells continued to express IL-17F at levels 
Figure 4.   T cells from B6.AhRd/d mice have 
reduced IL-22 expression. (A) Cytokines from 
supernatants of lung homogenates were analyzed 
by ELISA from WT C57BL/6 (wt) and B6.AhRd/d mice 
treated with either B. subtilis or PBS for 4 wk. The 
mean is shown as a solid line. Data are compiled 
from five individual mice from at least two separate 
experiments. (B) Representative density plots of 
intracellular IL-22, IL-17A, and IL-17F expression in 
 and CD4+ T cells isolated from the lung of B6.
AhRd/d mice treated with B. subtilis for 4 wk. 
 T cells expressing IL-22, IL-17A, or IL-17F were 
selected from a bivariate dot plot of CD3+/C+ cells 
from the lymphocyte gate. CD4+ T cells that express 
IL-22, IL-17A, and IL-17F were selected from a  
bivariate dot plot of CD3+/side scatter–expressing 
cells in the lymphocyte gate. The percentage of  
T cells expressing IL-22, IL-17A, or IL-17F is shown 
in the top right quadrant of the density plot. Data 
are representative of at least five individual mice per 
experiment from at least three separate experi-
ments. (C) Absolute number of IL-22–, IL-17A–, and 
IL-17F–expressing  T cells in the lung of B6.AhRd/d 
and WT C57BL/6 mice treated with B. subtilis for  
4 wk. Data represent five individual mice per experi-
ment from at least three separate experiments 
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mice treated with intratracheal rIL-22 and B. subtilis com-
pared with control mice exposed to vehicle and B. subtilis.   
In addition, no significant changes in the number of total 
lung cells or lymphocytes in WT C57BL/6 mice were seen 
(Fig. S2). There was no significant change in the number of 
 T cells in the lung of both WT C57BL/6 and AhRd/d 
mice treated with rIL-22 and B. subtilis (unpublished data). 
Conversely, CD4+ T cells were significantly decreased in 
WT C57BL/6, AhRd/d, and TCR-/ mice that received 
rIL-22 (Fig. 6 B), whereas treatment with rIL-22 alone had 
no effect on lung inflammation (not depicted).
Masson trichrome staining of lungs of AhRd/d and TCR-
/ mice treated with B. subtilis and rIL-22 showed reduced 
mononuclear cell infiltrates and collagen deposition in a peri-
bronchovascular distribution (Fig. 6 C). Using Sirius red col-
orimetric  assay  for  collagen  quantification,  AhRd/d  and 
TCR-/ mice that received intratracheal rIL-22 had de-
creased levels of collagen deposition in the lung compared 
with mice treated with B. subtilis alone. For example, there 
was  a  2-  and  1.5-fold  decrease  in  collagen  deposition  in 
AhRd/d mice treated with 100 ng and 100 pg of rIL-22, re-
spectively, compared with mice treated with B. subtilis alone 
(Fig. 6 D). TCR-/ mice also had a significant decrease in 
collagen deposition in the lung with a 1.6- and 1.3-fold de-
crease in collagen content in the lung of mice treated with 
100 ng and 100 pg of rIL-22, respectively, compared with 
TCR-/ mice exposed to B. subtilis alone (Fig. 6 D). WT 
C57BL/6 treated with the higher concentration of rIL-22 
(100 ng) had decreased collagen deposition compared with 
B. subtilis treatment alone, whereas V6+/+ mice, which have 
higher levels of IL-22 in the lung throughout the course of 
 B. subtilis exposure (Fig. 1 D), did not have any additional 
decrease in lung fibrosis at either dose of rIL-22 (Fig. 6 D).   
In combination, these data demonstrate that exogenous rIL-22 
is capable of modulating lung inflammation and fibrosis   
induced by chronic exposure to B. subtilis.
Inhibition of IL-22 expression increases lung inflammation 
and fibrosis
We next investigated whether inhibition of AhR signaling in 
V6/V1+  T cells would reduce IL-22 expression and   
accelerate the B. subtilis–induced inflammatory and fibrotic pro-
cess. Because V6+/+ mice have increased levels of IL-22 in 
the lung and develop significantly less inflammation and fi-
brosis, we treated these mice with a chemical inhibitor of 
AhR, CH-223191. CH-223191 is a novel chemical com-
pound that potently inhibits AhR-dependent transcription 
induced  by  2,3,7,8-Tetrachlorodibenzo-p-dioxin  (TCDD; 
Kim et al., 2006). In addition, CH-223191 has been shown 
to block binding of TCDD to AhR and inhibit TCDD- 
mediated nuclear translocation and DNA binding of AhR, 
thus preventing expression of target genes of AhR without 
detectable AhR agonist activity (Kim et al., 2006).
V6+/+ mice were treated with B. subtilis and either   
10 mM or 10 µM of CH-223191 for three consecutive days 
each week for four consecutive weeks. As shown in Fig. 7 A, 
(Simonian et al., 2009a). Collectively, these findings suggest 
that V6/V1+  T cells protect against lung fibrosis through 
expression of IL-22.
Recombinant IL-22 decreases lung inflammation  
and fibrosis in AhRd/d and TCR-/ mice
To confirm that IL-22 protects against B. subtilis–induced 
lung inflammation and fibrosis, we treated mice with de-
creased IL-22 production (i.e., AhRd/d and TCR-/ mice) 
with intratracheal rIL-22 (100 pg and 100 ng) in combination 
with B. subtilis for 3 d each week for four consecutive weeks. 
As shown in Fig. 6 A, total cells and lymphocytes were sig-
nificantly decreased in the lung of AhRd/d and TCR-/ 
Figure 5.  Defective AhR signaling accelerates lung fibrosis.  
(A) Representative Masson’s trichrome staining of lungs from WT 
C57BL/6, B6.AhRd/d, and B6.TCR/ mice repeatedly treated with B. subti-
lis or PBS for four consecutive weeks is shown. Arrow denotes collagen 
deposition in a peribronchovascular distribution. Data shown represent at 
least five mice from at least three separate experiments (40×). Bars, 100 µm. 
(B) Quantification of collagen content using Sirius red colorimetric assay 
shows increased collagen deposition in the lungs of individual B6.AhRd/d 
and B6.TCR/ (/) mice compared with WT C57BL/6 (wt) mice treated 
with B. subtilis or PBS for four consecutive weeks. The mean is shown as a 
solid line. Data were compiled from five individual mice from at least two 
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of  increased  numbers  of  CD4+  T  cells,  lung  fibrosis  was   
accelerated, as assessed by both Masson’s trichrome staining 
and quantitatively by Sirius red colorimetric assay, with a 
twofold increase in collagen deposition in the lung of V6+/+ 
mice treated with 10 mM CH-223191 compared with con-
trol mice treated in an identical manner with B. subtilis and   
vehicle (Fig. 7, E and F).
To directly determine if blocking IL-22 results in in-
creased  lung  inflammation  and  fibrosis,  we  treated  WT 
C57BL/6  and  TCR-/  mice  with  anti–IL-22  mAb  in 
combination with B. subtilis for 4 wk. Lung inflammation, as 
assessed by total cell numbers, was not significantly different 
between mice treated with the anti–IL-22 antibody com-
pared with isotype controls (Fig. 8 A). In contrast to  T cells 
in the lung of WT C57BL/6 mice, which were unaltered by   
the addition of the anti–IL-22 antibody, CD4+ T cells were 
treatment of V6+/+ mice with B. subtilis in combination 
with the AhR inhibitor resulted in decreased frequency of   
 T cells that express IL-22 compared with mice treated 
with B. subtilis and vehicle. In addition, the number of IL-22– 
expressing  T cells and the level of IL-22 in the lung were 
markedly  reduced  in  V6+/+  mice  treated  with  the  AhR   
inhibitor at both concentrations relative to mice treated with 
B. subtilis and vehicle (Fig. 7, B and C). With reduced IL-22 
expression, lung inflammation was accelerated with increased 
total cells, whereas the number of  T cells was relatively 
unaffected in the lung of V6+/+ mice treated with the AhR 
inhibitor compared with mice exposed to B. subtilis and ve-
hicle (Fig. 7 D). CD4+ T cells, however, were markedly in-
creased (more than threefold) in the lung of V6+/+ mice 
treated with the AhR inhibitor compared with mice exposed to 
B. subtilis treated with vehicle alone (Fig. 7 D). In the presence 
Figure 6.  B6.AhRd/d and B6.TCR/ mice treated with recombinant IL-22 have less lung inflammation and fibrosis. (A) Total and differential 
cell counts performed on lung homogenates from B6.AhRd/d (AhR) and B6.TCR/ (/) mice treated with a combination of recombinant IL-22 and  
B. subtilis or vehicle and B. subtilis for four consecutive weeks. Data were compiled from at least five mice per experiment from two separate experiments 
(mean ± SD). (B) Number of CD4+ T cells in the lung of WT C57BL/6 (wt), B6.AhRd/d (AhR), and B6.TCR/ (/) mice treated with a combination of  
recombinant IL-22 and B. subtilis or vehicle and B. subtilis for four consecutive weeks. Data were compiled from at least five mice per experiment from 
two separate experiments (mean ± SD). (C) Representative Masson’s trichrome staining of lungs from B6.AhRd/d, B6.TCR/, and WT C57BL/6 mice  
repeatedly treated with B. subtilis and recombinant IL-22 for four consecutive weeks is shown. Data shown represent at least five mice from at least two 
separate experiments (40×). Bars, 100 µm. (D) Quantification of collagen content using Sirius red colorimetric assay in the lungs of individual B6.AhRd/d, 
B6.TCR/, WT C57BL/6, and B6.V6+/+ mice compared with mice treated with B. subtilis or sterile PBS alone for four consecutive weeks is shown.  
The mean is shown as a solid line. Data were compiled from five individual mice from at least two separate experiments. NS, not significant. P > 0.05.2246  T cells in lung inflammation and fibrosis | Simonian et al.
significantly increased in the lung of WT C57BL/6 mice 
treated  with  anti–IL-22  antibody  compared  with  isotype 
control (Fig. 8 A). In the presence of an already exaggerated 
lung inflammatory response (Simonian et al., 2006), anti–IL-22 
antibody had no effect on the recruitment of CD4+ T cells to 
the lung of TCR-/ mice (Fig. 8 A). As shown in Fig. 8 B, 
WT  C57BL/6  mice  treated  with  anti–IL-22  antibody  had   
accelerated collagen deposition in the lung compared with 
mice treated in an identical fashion with an isotype control 
antibody. Exposure of TCR-/ mice to B. subtilis and 
anti–IL-22 antibody did not result in a further elevation of 
collagen deposition in the lung compared with mice treated 
with the isotype control (Fig. 8 B), likely because of the pres-
ence of significantly decreased IL-22 in the lung of TCR-/ 
mice relative to WT C57BL/6 mice (Fig. 1 D). Collectively, 
these data provide direct evidence that IL-22 regulates the 
accumulation of CD4+ T cells in the lung and B. subtilis– 
induced lung fibrosis.
CD4+ T cells promote lung fibrosis in response to B. subtilis
In the absence of  T cells, we have previously shown that 
an increased number of CD4+ T cells are recruited to the 
lung (Simonian et al., 2006). To determine whether the acti-
vation  and  differentiation  state  of  CD4+  cells  is  affected   
by the presence or absence of IL-22–secreting V6/V1+  
 T cells after B. subtilis exposure, we analyzed lung CD4+  
T cells from WT C57BL/6, TCR-/, and V4/6/ mice.   
As compared with CD4+ T cells from WT C57BL/6 mice, a 
significantly increased percentage of CD4+ T lymphocytes 
from the lung of TCR-/ and V4/6/ mice expressed 
high levels of CD44, a memory cell marker, and CD69, a 
marker of recent activation (Fig. 9 A). In addition, a reduced 
percentage  of  T  cells  expressed  CD45RB,  CD27,  and 
CD62L, indicating that a larger fraction of CD4+ T cells in   
B. subtilis–treated TCR-/ and V4//6/ mice had a 
Figure 7.  Acceleration of lung inflammation and fibrosis in trans-
genic V6/V1 mice treated with an AhR inhibitor. (A) Representative 
density plots of intracellular IL-22 expression in  T cells isolated from 
the lung of B6.V6+/+ mice treated with the AhR inhibitor CH-223191 and 
B. subtilis or B. subtilis with vehicle for four consecutive weeks.  T cells 
expressing IL-22 were selected from a bivariate dot plot of CD3+/side  
scatter cells from the lymphocyte gate. The percentage of CD3+ T cells in 
each quadrant of the density plot is shown. Data are representative of at 
least five individual mice per experiment treated with CH-223191 at each 
concentration with B. subtilis from at least two separate experiments.  
(B) Number of IL-22–expressing  T cells in the lung of B6.V6+/+ mice (+/+) 
treated with a combination of AhR inhibitor, CH-223191, and B. subtilis or 
B. subtilis and vehicle for four consecutive weeks. Data were compiled from 
at least five mice per experiment from two separate experiments (mean ± SD). 
(C) IL-22 concentration in the lung of B6.V6+/+ mice treated with a  
combination of AhR inhibitor, CH-223191, and B. subtilis or B. subtilis and 
vehicle for four consecutive weeks. The mean is shown as a solid line. Data 
were compiled from five individual mice from at least two separate experi-
ments. (D) Number of cells in the lung of B6.V6+/+ mice (+/+) treated with 
a combination of AhR inhibitor, CH-223191, and B. subtilis or B. subtilis and 
vehicle for four consecutive weeks. Data were compiled from at least five 
mice per experiment from two separate experiments (mean ± SD). (E) Rep-
resentative Masson’s trichrome staining of lungs from B6.V6+/+ mice 
repeatedly treated with the AhR inhibitor, CH-223191, and B. subtilis com-
pared with mice treated with B. subtilis and vehicle for four consecutive 
weeks is shown. Arrow denotes collagen deposition in a peribronchovascu-
lar distribution. Data shown represent at least five mice from at least two 
separate experiments (40×). Bars, 100 µm. (F) Quantification of collagen 
content using Sirius red colorimetric assay in the lungs of individual B6.
V6+/+ mice treated with the AhR inhibitor CH-223191 compared with 
mice treated with vehicle and B. subtilis or sterile PBS alone for four con-
secutive weeks is shown. The mean is shown as a solid line. Data were 
compiled from five individual mice from at least two separate experiments.
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by nasal inhalation (P < 0.01; Fig. 9 C). TCR-// mice 
reconstituted with CD8+ T cells also had a slight increase in col-
lagen content in the lung when chronically exposed to B. subtilis, 
compared with PBS-treated CD8+ T cell–reconstituted control 
mice. However, similar levels of collagen deposition were seen 
in B. subtilis–treated TCR-// mice that were sham re-
constituted by injecting sterile PBS into the tail vein (Fig. 9 C). 
Therefore, CD8+ T cells do not appear to have a significant role 
in the development of PF. Collectively, these data suggest that 
activated CD4+ T cells that accumulate in the lung in response 
to repeated B. subtilis exposure promote lung fibrosis.
rIL-22 reduces accumulation of CXCR3-expressing CD4+  
T cells in the lung
Although Th1 cells typically express CXCR3, Th17 cells 
have also been shown to express this chemokine receptor 
(Acosta-Rodriguez et al., 2007). In addition, CXCR3 ex-
pression has been shown to be important in other models of 
lung injury/fibrosis such as bleomycin-induced lung fibrosis 
(Jiang et al., 2004). To determine if IL-22 affects CXCR3 
expression on CD4+ T cells and recruitment of activated 
CD4+CXCR3+ T lymphocytes in the lung, we treated WT 
C57BL6,  Ahrd/d,  and  TCR-/  mice  with  rIL-22  and   
B. subtilis for 4 wk. As shown in Fig. 10 (A and B), the per-
centage and number of CXCR3-expressing CD4+ T cells 
isolated from the lung of WT C57BL6, Ahrd/d, and TCR-/ 
mice treated with rIL-22 was significantly decreased com-
pared with mice treated with B. subtilis and vehicle.
Next, we evaluated total lung homogenates from V6+/+, 
WT C57BL/6, and TCR-/ mice for the CXCR3 ligands 
CXCL9, 10, and 11. As shown in Fig. 10 C, levels of CXCL9 
and CXCL10 were significantly increased in the lung of   
TCR-/ mice compared with V6+/+ and WT C57BL/6 mice 
repeatedly exposed to B. subtilis over 4 wk, whereas CXCL11 
was no different between the various strains of mice. To deter-
mine if exogenous rIL-22 could alter the levels of CXCR3   
ligands in the lung, we treated WT C57BL/6, TCR-/, and 
AhRd/d mice with B. subtilis and rIL-22 for 4 wk. As shown in 
Fig. 10 D, levels of CXCL9 were decreased in the lung of WT 
C57BL/6 mice treated with 100 ng rIL-22 but not at the lower 
dose. CXCL9 levels, however, were decreased in the lung of 
TCR-/ and AhRd/d mice at both concentrations of rIL-22 
(Fig. 10 D). Levels of CXCL10 were not affected by treatment 
with rIL-22, suggesting that  T cells may affect CXCL10 
expression independent of IL-22 (Fig. S3). Conversely, levels 
of CXCL9 were increased in the lung of V6+/+ mice treated 
with B. subtilis for 4 wk in the presence of the AhR inhibitor 
CH-223191 (Fig. 10 E). Collectively, these data suggest that 
IL-22 alters the expression of the CXCR3 ligand CXCL9, re-
sulting in a reduced recruitment of CD4+CXCR3+ T cells to 
the lung in response to repeated exposure to B. subtilis.
DISCUSSION
We developed a mouse model of HP to investigate the role 
of different T cell subsets in lung inflammation and fibrosis 
induced by chronic exposure to a common environmental 
highly activated effector phenotype, as compared with those 
from the lung of WT C57BL/6 mice (Fig. 9 A).
To test whether CD4+ T cells represent a pathogenic   
T cell subset and promote lung fibrosis in response to B. sub-
tilis, we adoptively transferred CD4+ and CD8+ T cells from 
the spleen of naive WT C57BL/6 mice into TCR-// 
mice and subsequently treated them with B. subtilis by nasal 
inhalation.  As  shown  in  Fig.  9  B,  mice  receiving  CD4+  
T  cells  developed  peribronchovascular  mononuclear  infil-
trates similar to WT C57BL/6 mice treated in an identical 
fashion with B. subtilis (Fig. 9 B, top; Simonian et al., 2006, 
2009a). Although CD4+ T cells were found in the lung and 
spleen of all mice reconstituted with CD4+ T lymphocytes, 
much higher numbers of CD4+ T cells were obtained after 
repeated exposure to B. subtilis, compared with similar mice 
treated with inhaled PBS. Conversely, TCR-// mice 
reconstituted with CD8+ T cells did not show a significant 
accumulation of cells in the lung after subsequent exposure to 
either B. subtilis or PBS by nasal inhalation (Fig. 9 B).
As opposed to CD8+ T cells, the adoptive transfer of CD4+ 
T cells into B. subtilis–treated TCR-// mice also re-
sulted in lung fibrosis as detected by Masson trichrome (Fig. 9 B, 
bottom). In addition, quantification of collagen deposition by 
Sirius red colorimetric assay showed a 2.9-fold increase in colla-
gen content in the lungs of these mice, as compared with CD4+ 
T cell–reconstituted control mice that were treated with PBS   
Figure 8.  Administration of anti–IL-22 enhances the B. subtilis–
induced CD4+ T cell alveolitis and accelerates lung fibrosis. (A) Total 
and differential cell counts performed on lung homogenates from WT 
C57BL/6 (wt) and B6.TCR/ (/) mice treated with B. subtilis in com-
bination with anti–IL-22 (IL-22) or isotype control (IC) for 3 d a week for 
four consecutive weeks is shown. Data were compiled from at least five 
individual mice from two separate experiments (mean ± SD). (B) Quantifi-
cation of collagen content using Sirius red colorimetric assay in the lungs 
of individual WT C57BL/6 (wt) and B6.TCR/ (/) mice treated with  
B. subtilis in combination with anti–IL-22 (IL-22) or isotype control (IC) 
for 3 d a week for four consecutive weeks is shown. The mean is shown as 
a solid line. Data represent five individual mice per experiment from two 
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microorganism, B. subtilis (Simonian et al., 2006). In this 
model, V6/V1+  T cells expand in the lung in response 
to the microorganism and attenuate B. subtilis–induced lung 
inflammation and fibrosis (Simonian et al., 2006). In addi-
tion to IL-17A, the current study shows that V6/V1+  
 T cells isolated from the lung of mice chronically exposed 
to B. subtilis express IL-22 and that expression of IL-22 is an 
important mechanism by which these T cells attenuate lung 
inflammation and fibrosis.
V6/V1+  T cells are a rare population of  T cells 
that normally reside in the female reproductive tract (Itohara 
et al., 1990), tongue (Itohara et al., 1990), and lung (Sim et al., 
1994) but are rarely found in other tissues (Roark et al., 2004). 
Expansions of this TCR-invariant subset have been reported 
in  the  liver  of  Listeria  monocytogenes–infected  mice  (Roark   
et al., 1996), testis during Listeria-induced orchitis (Mukasa   
et  al.,  1997),  peritoneum  of  Escherichia  coli–infected  mice 
(Matsuzaki, Takada, and Nomoto, 1999), kidneys of mice in-
fected intrarenally with L. monocytogenes (Ikebe et al., 2001), 
kidneys of rats treated with adriamycin (Ando et al., 2001), 
and brains of mice with experimental autoimmune encephali-
tis (Olive, 1995). In response to intratracheal B. subtilis, the 
lung  T cell expansion is almost completely limited to the 
V6/V1+  T cell subset and substantially exceeds that of 
both CD4+ and CD8+ -expressing T cells (Simonian et al., 
2006, 2009a). As a result of its invariant TCR, it is likely that 
the TCR ligand for V6/V1+  T cells is a host molecule 
whose expression is induced during inflammation. How-
ever, we and others have previously shown that live bacteria 
are required to induce a  T cell response (Griffin et al., 
1991; Boom et al., 1992; Skeen and Ziegler, 1993; Simonian 
et al., 2006).
Consistent with previous studies (Weaver et al., 2007; 
Veldhoen et al., 2008, 2009; Simonian et al., 2009a), we iden-
tified distinct populations of V6/V1+  T cells that differ-
entially express IL-17A and IL-22. In addition, IL-17A and 
IL-17F were also differentially expressed, with IL-22 expres-
sion identified as a subset of IL-17F–expressing V6/V1+  
 T cells. These findings suggest that distinct V6/V1+  
 T cell subsets may possess a range of functional capabilities. 
Recent data suggest that IL-17A and IL-17F may have com-
plementary roles in host defense against Staphylococcus aureus 
(Ishigame et al., 2009). IL17a/IL17f/ mice were more 
susceptible to mucocutaneous abscesses that contained S. au-
reus than either IL17a/ or IL17f/ mice, suggesting that   
S. aureus infection can be independently controlled by IL-17A 
or IL-17F (Ishigame et al., 2009). Although IL-17A and IL-17F 
bind to the same receptors, the binding affinities of IL-17A 
Figure 9.  CD4+ T cells represent the pathogenic T cell subset and 
induce lung fibrosis. (A) Expression of CD44, CD69, CD45RB, CD27, and 
CD62L on CD4+ T cells isolated from the lungs of WT C57BL/6, TCR-/, 
and V4/6/ mice treated with B. subtilis for 4, 8, and 12 consecutive 
weeks is shown. Data represent the mean ± SD of at least five mice at each 
time point treated with B. subtilis from at least two separate experiments. 
The asterisks denote a statistically significant (P < 0.05) difference in the 
percentage of CD4+ T cells that express each surface marker from the lung 
of WT C57BL/6 compared with TCR-/ mice treated with B. subtilis at 
each time point. (B) Representative H&E (top) and Masson trichrome (bot-
tom) staining of lungs from TCR-// mice reconstituted with either 
CD4+ or CD8+ T cells or sterile PBS followed by intranasal treatment with 
either B. subtilis or sterile PBS for four consecutive weeks is shown. Arrow-
head denotes mononuclear infiltrates in the peribronchovascular space. 
Arrow denotes collagen deposition in a peribronchovascular distribution. 
Data represent at least four individual mice from at least two separate 
experiments for H&E and Masson Trichrome staining (40×). Bars, 100 µm. 
(C) Quantification of collagen content using Sirius Red by colorimetric 
assay in the lungs of individual TCR-// (//) mice reconsti-
tuted with CD4+, CD8+, or sterile PBS by tail vein injection followed by 
repeated intranasal treatment with B. subtilis (Bsub) or sterile PBS for four 
consecutive weeks. The mean is shown as a solid line. Data were compiled 
from five individual mice from at least two separate experiments.
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likely  determines  where  they  exert 
their functional capabilities (Gaffen, 
2009). IL-17RA mRNA was shown to 
be highly expressed in lymphoid tissues 
such as the thymus, spleen, and lymph 
nodes, whereas IL-17RC mRNA was 
expressed in nonhematopoietic tissues 
such as the colon, small intestine, and 
lung (Ishigame et al., 2009), with IL-22 
receptor expression reported on bronchial epithelial cells   
(Aujla et al., 2008). Collectively, these data suggest that IL-17A–
expressing V6/V1+  T cells most likely exert their function 
on hematopoietic tissue to promote elimination of the micro-
organism, whereas the population of V6/V1+  T cells 
and  IL-17F  for  IL-17RA  and  IL-17RC  may  be  different   
(Hymowitz et al., 2001; Kuestner et al., 2007; Wright et al., 
2008). In mice, IL-17RA binds both IL-17A and IL-17F, but 
IL-17RC interacts with only IL-17F (Kuestner et al., 2007). 
Therefore, tissue distribution of the receptors for these cytokines 
Figure 10.  Recombinant IL-22 decreases 
CXCR3 expression by CD4+ T cells and levels 
of CXCL9 in the lung. (A) Representative den-
sity plots of CXCR3 expression by CD4+ T cells 
isolated from the lung of WT C57BL6, B6.AhRd/d, 
and B6.TCR/ mice treated with a combina-
tion of recombinant IL-22 and B. subtilis or 
vehicle and B. subtilis for four consecutive 
weeks. CD4+ T cells were selected from a bivari-
ate dot plot of CD3+CD4+ cells from the lym-
phocyte gate. The percentage of CD3+CD4+  
T cells expressing CXCR3 is shown in the top right 
quadrant of the density plot. Data represent at 
least five individual mice per experiment from 
two separate experiments. (B) Number of 
CXCR3-expressing CD4+ T cells in the lung of 
WT C57BL/6 (wt), B6.AhRd/d (AhR), and B6.
TCR/ (/) mice treated with a combina-
tion of recombinant IL-22 and B. subtilis or 
vehicle and B. subtilis for four consecutive 
weeks. Data were compiled from at least five 
individual mice per experiment from two sepa-
rate experiments. (C) Levels of CXCL9, 10, and 11 
in the lung of WT C57BL/6 (), B6.V6+/+ (), 
and B6.TCR/ () mice treated with B. subti-
lis for four consecutive weeks compared with 
PBS control. The asterisks denote a statistically 
significant (P < 0.05) difference in lung chemo-
kine concentration at each time point between 
B6.TCR/ and B6.V6+/+ mice. Data were 
compiled from at least five individual mice at 
each time point from two separate experiments 
(mean ± SD). (D) Levels of CXCL9 in the lung of 
WT C57BL/6, TCR-/, and AhRd/d mice treated 
with a combination of recombinant IL-22 and  
B. subtilis, B. subtilis, or PBS for four consecutive 
weeks. The mean is shown as a solid line. Data 
were compiled from five individual mice from 
two separate experiments. (E) Levels of CXCL9 in 
the lung of B6.V6+/+ mice treated with a com-
bination of the AhR inhibitor, CH-223191, and 
B. subtilis, B. subtilis, or PBS for four consecutive 
weeks. The mean is shown as a solid line. Data 
were compiled from five individual mice from 
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however,  we  found  increased  numbers  of  activated  CD4+  
T cells in the lung of mice deficient in IL-22–expressing   
V6/V1+  T cells and accelerated lung fibrosis. Upon 
treatment with recombinant IL-22, AhRd/d and TCR-/ 
mice not only had reduced collagen deposition but also a di-
minished CD4+ T cell alveolitis. Conversely, transgenic V6+/+ 
mice treated with the AhR inhibitor CH-23191 had decreased 
levels of IL-22 and increased numbers of CD4+ T cells in the 
lung that resulted in loss of protection against B. subtilis– 
induced lung fibrosis. In addition, neutralization of IL-22 by 
treatment with an anti–IL-22 mAb resulted in elevated num-
bers of CD4+ T cells and acceleration of lung fibrosis. Adop-
tive transfer of CD4+ T cells into mice deficient in both  
and  T cells resulted in collagen deposition in the lung, fur-
ther implicating CD4+ T lymphocytes in the pathogenesis of 
B. subtilis–induced lung fibrosis.
Th17 cytokines induce numerous chemokines and growth 
factors to promote cellular recruitment to the site of in-
jury (for review see Alcorn et al., 2010). In the absence of   
 T cells and the resultant diminution in IL-22 expression 
in our model, the lungs of B. subtilis–treated TCR-/ mice 
contain a significantly greater number of CD4+CXCR3+  
T cells that express an activated effector phenotype as compared 
with WT C57BL/6 mice. The diminished CD4+CXCR3+ 
T cell inflammatory response in WT C57BL/6, TCR-/, 
and AhRd/d mice as a result of exogenous rIL-22 administra-
tion suggests that the mechanism by which IL-22 decreases 
CD4+ T cell recruitment to lung in response to B. subtilis is 
through decreased expression of CXCR3 ligands. Consistent 
with this observation, levels of the CXCR3 ligand CXCL9 
were decreased in the lung of both AhRd/d and TCR-/ 
mice in response to rIL-22. Because the IL-22 receptor and 
expression of CXCL9 have been demonstrated on lung epi-
thelial cells (Aujla et al., 2008), rIL-22 may decrease ex-
pression of CXCL9 by lung epithelial cells that limit the 
recruitment of CD4+CXCR3+ T cells to the lung in response 
to repeated exposure to B. subtilis.
The fact that lung fibrosis was not completely abrogated in 
AhRd/d and TCR-/ mice treated with rIL-22 raises the 
possibility that either higher levels of IL-22 in lung are re-
quired or other factors expressed by  T cells are necessary to 
further reduce collagen deposition in the lung. Therefore,   
IL-17A,  IL-17F,  or  other  factors  expressed  by  V6/V1+  
 T cells may still act synergistically with IL-22 to reduce CD4+ 
T cell recruitment to the lung and, thus, lung fibrosis. How-
ever, the presence of an exaggerated B. subtilis–induced   
fibrotic response in AhRd/d and TCR-/ mice, despite high 
levels of IL-17A and IL-17F in the lung, strongly suggests that 
IL-22 is the more critical Th17 cytokine for protecting against 
lung fibrosis induced by chronic exposure to B. subtilis.
Although  cessation  of  antigen  exposure  often  improves 
lung inflammation, irreversible PF still develops in 41% of 
HP subjects and is associated with increased morbidity and 
mortality (Vourlekis et al., 2004). Current therapeutic options 
for HP patients are limited to corticosteroids which nonspecif-
ically suppress T cell function. The ability of rIL-22 to regulate 
that express IL-22 and IL-17F may protect epithelial integrity 
in the lung through IL-22 receptor or IL-17RC signaling.
Because recent studies show that AhR signaling is impor-
tant for IL-22 expression by - and -expressing T cells 
(Veldhoen et al., 2008; Martin et al., 2009), we analyzed and 
found substantial reductions in IL-22 levels in the lung of   
B. subtilis–treated AhRd/d mice as well as reduced IL-22 expres-
sion by V6/V1+  T cells, whereas IL-17A and IL-17F ex-
pression was unaffected. With the reduction in IL-22 levels in 
the lung of B. subtilis–treated AhRd/d mice, lung fibrosis was 
accelerated. The corroboration of these findings using an anti–
IL-22 mAb suggests that IL-22 plays a critical role in regulating 
collagen deposition in the lung. We recently showed that in 
the absence of IL-17A receptor signaling, IL-17ra/ mice had 
delayed clearance of B. subtilis and increased lung inflammation 
and fibrosis (Simonian et al., 2009a). Conversely, despite re-
duced IL-22 expression, AhRd/d mice chronically exposed to 
B. subtilis had no defects in bacterial clearance (Fig. S4), likely 
because of an unaffected IL-17A response. Although synergy 
between IL-17A and IL-22 cannot be excluded, these data 
support  the  concept  that  IL-17A–expressing  V6/V1+  
 T cells promote microbial elimination, whereas the IL-22– 
expressing population limits lung inflammation and fibrosis.   
In the bleomycin model of lung inflammation and fibrosis, 
however, IL-17A is necessary for lung fibrosis either through 
IL-1 (Wilson et al., 2010) or complex interactions that regu-
late IL-22 expression and function (Sonnenberg et al., 2010). 
In addition, IL-17A has been shown to be pathogenic in an-
other model of HP induced by repeated exposure to Saccha-
ropolyspora rectivirgula (Joshi et al., 2009; Simonian et al., 2009b). 
Therefore, whether IL-17A and IL-22 protect or promote 
lung inflammation and fibrosis is likely dependent on the 
inhaled agent.
IL-22 has emerged as an important cytokine in mucosal 
immunity (Aujla and Kolls, 2009). The mechanisms by which 
IL-22 protects epithelial structures in the lung, gut, and other 
organ systems from damage induced by numerous environ-
mental insults are under intense investigation. Emerging data 
suggest that IL-22 may provide mucosal protection by induc-
ing antimicrobial peptides from epithelial cells in the lung, gut, 
and skin as well as maintaining epithelial integrity either by 
preventing injury or accelerating epithelial repair after a variety 
of insults (Liang et al., 2006; Zheng et al., 2007, 2008; Aujla   
et al., 2008). In a mouse model of host defense against Gram-
negative bacterial infection, WT mice given anti–IL-22 anti-
body before lung infection with Klebsiella pneumoniae had 
greater dissemination of infection and increased mortality than 
mice given a control antibody (Aujla et al., 2008). The combi-
nation of IL-17A and IL-22 significantly increased expression 
of an antimicrobial protein, lipocalin-2, in mouse tracheal epi-
thelial cells, suggesting that IL-22 and IL-17A act synergisti-
cally, although IL-22 was shown to be more important for 
microbial elimination (Aujla et al., 2008). IL-22 was also found 
to induce clonogenic potential in human bronchial epithelial 
cells as well as enhanced recovery of epithelial resistance after 
epithelial injury (Aujla et al., 2008). In the B. subtilis model, JEM VOL. 207, September 27, 2010 
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Cytokine analysis and collagen quantification. Total lung homogenates 
were prepared by homogenizing whole lung samples in 500 µl of sterile PBS 
from each group of mice treated with either B. subtilis or sterile PBS for four 
consecutive weeks. 100 µl of supernatant from each lung homogenate was 
analyzed for cytokines by ELISA for IL-17A (eBioscience), IL-17F, IL-22, 
CXCL9, CXCL10, and CXCL11 (R&D Systems) according to the manufac-
turer’s instructions. The collagen content of the right lung was determined 
using Sirius Red staining as previously described (Simonian et al., 2006).
Total and differential cell counts. Total and differential cell counts were 
performed on collagenase-digested lung before purification of mononuclear 
cells over Ficoll as previously described (Simonian et al., 2006, 2009b).   
In brief, single-cell suspensions of total lung cells were transferred to a glass 
slide using a cytocentrifuge apparatus and stained with Wright and Giemsa 
per manufacturer’s instructions. Epithelial cells were not included in the total 
cell count and RBCs were removed by RBC lysis. Differential cell counts 
were performed by counting at least 400 cells under a high power field.
Adoptive transfer experiments. CD4+ and CD8+ T cells were isolated 
from spleens of untreated C57BL/6 mice and purified by MACS (Miltenyi 
Biotec) using negative selection for either CD4+ or CD8+ T lymphocytes. 
Flow cytometry confirmed >95% purity for each T cell population before 
adoptive transfer of 5 × 105 cells/100 µl of sterile PBS by tail vein injection 
into TCR-// mice. In brief, total splenocytes were obtained by push-
ing spleens through a 70-µm pore-size mesh (Falcon) with subsequent resus-
pension in RBC lysis buffer (eBioscience). Cells were resuspended in buffer 
and biotinylated antibody cocktail, mixed, and incubated at 4°C for 10 min. 
Anti-biotin microbeads were added per the manufacturer’s instructions, mixed, 
and incubated for 15 min at 4°C. The cells were washed and applied to the 
column per the manufacturer’s instructions. The effluent, which contained the 
unlabeled CD4+ or CD8+ T cells, was collected and passed over a second col-
umn to further enrich each T cell population. Cell counts for CD4+ and CD8+ 
T lymphocytes were determined by Coulter counter (Beckman Coulter).
Statistical analysis. A Mann-Whitney U analysis and one-way ANOVA with 
a Bonferroni’s multiple comparison test were used to determine whether there 
were significant differences between the treatment groups at each time point 
(Prism 4; GraphPad Software). P < 0.05 was considered statistically significant.
Online supplemental material. Fig. S1 demonstrates that IL-17A and 
IL-22 are not expressed by  T cells isolated from the spleen of homo-
zygous  transgenic  V6/V1  (B6.V6+/+)  mice  repeatedly  exposed  to   
B. subtilis. Fig. S2 shows that recombinant IL-22 does not decrease levels of 
CXCL10 in the lung. Fig. S3 demonstrates the absence of an effect of rIL-22 
on CXCL10 levels in the lung of TCR-/ mice. Fig. S4 demonstrates 
similar clearance of B. subtilis from the lung of AhRd/d and WT C57BL/6 
mice. Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20100061/DC1.
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